U.S. FDA Completes Inspection Of Lupin’s Vizag API Facility

Pharma major Lupin Limited (Lupin) today announced the completion of an inspection carried out by the United States Food and Drug Administration (U.S. FDA) at its Vizag API manufacturing facility. The inspection was carried out between January 13, 2020 and January 17, 2020.

The inspection for the API facility at Vizag closed with five 483 observations.

Commenting on the outcome of the inspection, Nilesh Gupta, Managing Director, Lupin said, “We are fully committed to adherence with CGMP regulations and uphold high quality standards across all our manufacturing sites. We are confident of addressing the observations to the U.S. FDA’s satisfaction”.

Shares of LUPIN LTD. was last trading in BSE at Rs.766.25 as compared to the previous close of Rs. 754.15. The total number of shares traded during the day was 86240 in over 2550 trades.

The stock hit an intraday high of Rs. 770 and intraday low of 752.2. The net turnover during the day was Rs. 65657367.-Equity Bulls

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.